Lineage Cell Therapeutics Reports Positive 36-Month OpRegen Data and Manufacturing Milestones in 2025
核心洞察
Lineage Cell Therapeutics reported positive 36-month Phase 1/2a clinical data for OpRegen cell therapy, showing sustained visual acuity gains and retinal structural support in geographic atrophy (搜索) patients.
The company achieved its first milestone payment under the $620 million collaboration with Roche and Genentech, based on manufacturing and clinical advancements for the OpRegen program.
Lineage successfully demonstrated large-scale production capabilities through its AlloSCOPE platform, completing cGMP production runs that could enable millions of doses from a single cell line.
Lineage Cell Therapeutics achieved significant clinical and manufacturing milestones in 2025, highlighted by positive long-term data from its OpRegen cell therapy program and successful demonstration of its proprietary manufacturing platform capabilities.
OpRegen Shows Sustained Benefits at 36 Months
The company's lead program, OpRegen cell therapy (RG6501), demonstrated encouraging long-term outcomes in a Phase 1/2a clinical study for geographic atrophy (搜索) secondary to age-related macular degeneration (搜索). Clinical data reported at 12-, 24-, and 36-months for Cohort 4 of the Phase 1/2a study (12 patients) continues to demonstrate a consistent and durable treatment effect, with OpRegen-treated eyes exhibiting mean best corrected visual acuity (BCVA) scores above baseline at each of these timepoints in patients with less advanced disease.
Notably, five patients who received significant coverage of OpRegen cell therapy across their geographic atrophy (搜索) lesion are demonstrating long-term outcomes consistent with meaningful disease stabilization and even improvement. The positive results suggest evidence of sustained gains in visual acuity and structural support of the retina following a single administration of the retinal pigment epithelial cell therapy.
Manufacturing Milestone Triggers Roche Payment
Lineage achieved the first milestone available under its worldwide collaboration with Roche and Genentech, based on manufacturing and clinical advancements related to the OpRegen cell therapy program. This milestone is part of up to $620 million in potential milestone payments available under the collaboration agreement.
The ongoing Phase 2a GAlette Study is currently enrolling at 17 clinical sites in the U.S. and Israel. Genentech currently plans to evaluate proprietary surgical delivery devices that have potential advantages over available off-the-shelf devices in the Phase 2a GAlette Study, in addition to testing other surgical parameters.
AlloSCOPE Platform Demonstrates Scale Potential
The company successfully completed a production run for two product candidates using its proprietary AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) manufacturing platform. Each product was produced from a customized, two-tiered cGMP cell banking system, highlighting the application of the Lineage platform across multiple programs.
This production process utilizes a genetically-stable master cell bank created from a single, well-characterized pluripotent cell line, to generate a working cell bank, which then provides the source material for a final cell-based product candidate. The demonstrated cGMP production process should enable the ability to produce millions of doses of a cost-effective, scalable and consistent supply of an allogeneic, cell-based product derived from a single initial cell line, that can be applied across multiple programs.
Pipeline Expansion and New Collaborations
Lineage entered a research collaboration with William Demant Invest (搜索) A/S (WDI) to jointly advance preclinical development of ReSonance (搜索) (ANP1) for sensorineural hearing loss (搜索) over a term of three years. Up to $12 million of development costs will be contributed by WDI in a collaboration intended to cover planned preclinical development activities, including cell manufacturing, proof-of-concept studies, translational/functional models, delivery development, outcome measures, regulatory strategy, and market analysis.
The company also launched a new cell therapy research initiative (ILT1), focused on addressing the issue of large-scale production of undifferentiated pluripotent cells. The initial goal is establishing a production modality that can support the entire production process through differentiation in a dynamic culturing system, which if successful could potentially solve a major hurdle to commercialization of islet cell therapy product candidates for Type 1 diabetes (搜索) treatment.
Spinal Cord Injury Program Advances
Lineage treated the first chronic spinal cord injury (搜索) (SCI) patient in the DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The first treated participant had a neurologically complete SCI injury (American Spinal Injury Association Impairment Scale [AIS] grade A), with a single neurological level of injury from levels T1 to T10. The novel delivery system successfully administered a one-time injection of OPC1, and no significant safety events were reported 180 days following treatment.
Financial Position and Outlook
"2025 was a very productive year for the Lineage team," stated Brian M. Culley, Lineage CEO. "Our mission is to pioneer the emerging field of allogeneic cell therapy outside of oncology by applying our proprietary cell manufacturing technology platform, AlloSCOPE, to the production and transplantation of differentiated cell types, which are intended to replace the cells which a patient has lost, or lost function of, due to various conditions."
The company reported cash, cash equivalents, and marketable securities of $55.8 million as of December 31, 2025, together with approximately $5.4 million in proceeds from warrant exercises in March 2026, which is expected to support planned operations into the second quarter of 2028.
Total revenues for 2025 were $14.6 million, a net increase of $5.1 million compared to $9.5 million in 2024. The increase was primarily driven by higher collaboration revenue recognized under the Roche Agreement following achievement of the first milestone, along with the new research collaboration agreement with WDI.